Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation

  • Bernard Ng
  • , Andrew C. Harris
  • , Sayeh Abdossamadi
  • , Geraldine Aubert
  • , Rajinder Bajwa
  • , Monica Bhatia
  • , Henrique Bittencourt
  • , Nataliya P. Buxbaum
  • , Emi H. Caywood
  • , Sonali Chaudhury
  • , Joseph H. Chewning
  • , Sung Won Choi
  • , Ashley Chopek
  • , Julia Chu
  • , Donald Coulter
  • , Shahinaz M. Gadalla
  • , Richard T. Hogg
  • , David A. Jacobsohn
  • , Amanda K. Johnson
  • , Michael Joyce
  • Kimberly A. Kasow, Michael Kent, Carrie L. Kitko, Donna Lau, Anita Lawitschka, Victor A. Lewis, Amanda M. Li, Laura McLaughlin, David Mitchell, Eneida R. Nemecek, Vaishnavi Parthasarathy, Anna B. Pawlowska, Filip Pirsl, Michael A. Pulsipher, Muna Qayed, Jacob Rozmus, Süreyya Savaşan, Tal Schechter, Shalini Shenoy, Alima Suleimenova, Dong Jun Zheng, Elena Ostroumov, Andrew Gilman, Ramon I. Klein Geltink, Daniel Wolff, Geoffrey D.E. Cuvelier, Kirk R. Schultz

Research output: Contribution to journalArticlepeer-review

Abstract

Chronic graft-versus-host-disease (cGVHD) is the primary nonrelapse limitation to a successful hematopoietic cell transplantation and is largely treated as a single biological entity. We hypothesized that there exist different biological subtypes of cGVHD. Using the Applied Biomarkers of Late Effects of Childhood Cancer (ABLE) network database, which is derived from the largest pediatric cGVHD cohort worldwide, we applied clustering analysis to subtype patients with cGVHD from the ABLE1.0 and 2.0 studies (51 patients with cGVHD and 158 with non-cGVHD). We found 3 distinct cGVHD subtypes: cGVHD-1 was characterized by an effector memory T-cell, cytotoxic natural killer cell, and early precursor B-cell predominant pattern; cGVHD-2 was phosphatidylcholine, cytokine, and plasma cell predominant; and cGVHD-3 had more naïve CD4+T cells and naïve regulatory T cells, had later onset, and was the only subtype with measurable T-cell receptor excision circles. We partially replicated these subtypes using metabolomic data from a separate pediatric cohort of the Children’s Oncology Group trial ASCT0031 (33 patients with cGVHD and 39 with non-cGVHD). Furthermore, cGVHD-1 was associated with serotherapy (predominantly antithymocyte globulin) exposure, and cGVHD-3 was associated with receiving peripheral blood stem cells from donors, total body irradiation, and no previous acute GVHD. cGVHD-2 was associated with liver involvement and cGVHD-2 and -3 with de novo cGVHD. Overall, none of the subtypes were closely associated with organ involvement. Contrasting each subtype against patients with non-cGVHD, the 3 subtypes shared common markers, all of which were used in our previous cGVHD diagnostic classifier. These findings suggest the presence of distinct biological subtypes of cGVHD that may help guide therapeutic strategies.

Original languageEnglish
Pages (from-to)241-253
Number of pages13
JournalBlood
Volume147
Issue number3
DOIs
StatePublished - Jan 15 2026

Fingerprint

Dive into the research topics of 'Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation'. Together they form a unique fingerprint.

Cite this